1
|
Trépo C, Chan HL and Lok A: Hepatitis B
virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Hatzakis A, Van Damme P, Alcorn K, Gore C,
Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H,
Deuffic-Burban S, et al: The state of hepatitis B and C in the
Mediterranean and Balkan countries: Report from a summit
conference. J Viral Hepat. 20(Suppl 2): 1–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hösel M, Quasdorff M, Wiegmann K, Webb D,
Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S,
Kirschning CJ, et al: Not interferon, but interleukin-6 controls
early gene expression in hepatitis B virus infection. Hepatology.
50:1773–1782. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Mildner A and Jung S: Development and
function of dendritic cell subsets. Immunity. 40:642–656. 2014.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Hänninen A: New dimensions for dendritic
cells. Duodecim. 130:883–891. 2014.In Finnish.
|
6
|
Wang FS, Xing LH, Liu MX, Zhu CL, Liu HG,
Wang HF and Lei ZY: Dysfunction of peripheral blood dendritic cells
from patients with chronic hepatitis B virus infection. World J
Gastroenterol. 7:537–541. 2001. View Article : Google Scholar
|
7
|
Hao HX, Zhang YL, Li MH, Zhang LX, Yi W,
Hu YH, Yi N, Cheng J, Liu SA and Xie Y: Dendritic cell subsets and
function in newborns from mothers of different HBV infection
status. Zhong Hua Shi Yan He Lin Chuang Bing Du Xue Za Zhi.
27:112–114. 2013.In Chinese.
|
8
|
Ganem D and Prince AM: Hepatitis B virus
infection-natural history and clinical consequences. N Engl J Med.
350:1118–1129. 2004. View Article : Google Scholar : PubMed/NCBI
|
9
|
Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu
Y, Zhang Q, Wang J, Zhang Z, Shen F and Yuan Z: Expression profiles
and function of Toll-like receptors 2 and 4 in peripheral blood
mononuclear cells of chronic hepatitis B patients. Clin Immunol.
128:400–408. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu
M, Shi B, Chen J, Hu Y and Yuan Z: Hepatitis B virus surface
antigen selectively inhibits TLR2 ligand-induced IL-12 production
in monocytes/macrophages by interfering with JNK activation. J
Immunol. 190:5142–5151. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang
Z, Shen F, Zhang Q, Sun S and Yuan Z: HBsAg inhibits TLR9-mediated
activation and IFN-alpha production in plasmacytoid dendritic
cells. Mol Immunol. 46:2640–2646. 2009. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kondo Y, Ninomiya M, Kakazu E, Kimura O
and Shimosegawa T: Hepatitis B surface antigen could contribute to
the immunopatho-genesis of hepatitis B virus infection. ISRN
Gastroenterol. 2013:9352952013. View Article : Google Scholar
|
13
|
Zhang XM and Shan NN: The role of T cell
immunoglobulin and mucin domain-3 in immune thrombocytopenia. Scand
J Immunol. 79:231–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Khademi M, Illés Z, Gielen AW, Marta M,
Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris
RA, et al: T Cell Ig- and mucin-domain-containing molecule-3
(TIM-3) and TIM-1 molecules are differentially expressed on human
Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear
cells in multiple sclerosis. J Immunol. 172:7169–7176. 2004.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
16
|
Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia
Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased
Tim-3 expression are related to poor prognosis in gastric cancer.
PLoS One. 8:e817992013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chapuis F, Rosenzwajg M, Yagello M, Ekman
M, Biberfeld P and Gluckman JC: Differentiation of human dendritic
cells from monocytes in vitro. Eur J Immunol. 27:431–441. 1997.
View Article : Google Scholar : PubMed/NCBI
|
18
|
van der Molen RG, Sprengers D, Binda RS,
de Jong EC, Niesters HG, Kusters JG, Kwekkeboom J and Janssen HL:
Functional impairment of myeloid and plasmacytoid dendritic cells
of patients with chronic hepatitis B. Hepatology. 40:738–746. 2004.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Jan RH, Lin YL, Chen CJ, Lin TY, Hsu YC,
Chen LK and Chiang BL: Hepatitis B virus surface antigen can
activate human monocyte-derived dendritic cells by nuclear factor
kappa B and p38 mitogen-activated protein kinase mediated
signaling. Microbiol Immunol. 56:719–727. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Romani N, Reider D, Heuer M, Ebner S,
Kämpgen E, Eibl B, Niederwieser D and Schuler G: Generation of
mature dendritic cells from human blood. An improved method with
special regard to clinical applicability. J Immunol Methods.
196:137–151. 1996. View Article : Google Scholar : PubMed/NCBI
|
21
|
Op den Brouw ML, Binda RS, van Roosmalen
MH, Protzer U, Janssen HL, van der Molen RG and Woltman AM:
Hepatitis B virus surface antigen impairs myeloid dendritic cell
function: A possible immune escape mechanism of hepatitis B virus.
Immunology. 126:280–289. 2009. View Article : Google Scholar :
|
22
|
Jan RH, Lin YL, Chen LK, Huang MT, Wang LC
and Chiang BL: Hepatitis B virus surface antigen can activate
dendritic cells and modulate T helper type immune response.
Microbiol Immunol. 55:51–59. 2011. View Article : Google Scholar
|
23
|
Shen M, Wang S, Ge G, Xing Y, Ma X, Huang
Z and Lu S: Profiles of B and T cell immune responses elicited by
different forms of the hepatitis B virus surface antigen. Vaccine.
28:7288–7296. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Du X, Wang J, Kang Y, Xiao W, Zhao G and
Wang B: Suppression of the antigen-specific T cell immune response
by co-immunization with the HBV DNA vaccine and recombinant HBsAg.
Wei Sheng Wu Xue Bao. 49:938–942. 2009.In Chinese. PubMed/NCBI
|
25
|
Tong HS, Zhang Y, Yuan K and Fu XW: HBsAg
loading on dendritic cells in patients with chronic hepatitis B:
Expressions of phenotypic molecules. Hepatobiliary Pancreat Dis
Int. 5:56–59. 2006.PubMed/NCBI
|
26
|
Kang P, Luo SL and Li SC: Comparative
study on dendritic cells stimulated with HBsAg or HBcAg in patients
with chronic hepatitis B. Zhong Hua Shi Yan He Lin Chuang Bing Du
Xue Za Zhi. 21:250–252. 2007.In Chinese.
|
27
|
Han G, Chen G, Shen B and Li Y: Tim-3: An
activation marker and activation limiter of innate immune cells.
Front Immunol. 4:4492013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Anderson AC, Anderson DE, Bregoli L,
Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW,
Hirashima M, et al: Promotion of tissue inflammation by the immune
receptor Tim-3 expressed on innate immune cells. Science.
318:1141–1143. 2007. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kanzaki M, Wada J, Sugiyama K, Nakatsuka
A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Eguchi
J, et al: Galectin-9 and T cell immunoglobulin mucin-3 pathway is a
therapeutic target for type 1 diabetes. Endocrinology. 153:612–620.
2012. View Article : Google Scholar
|
30
|
Chiba S, Baghdadi M, Akiba H, Yoshiyama H,
Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan
JD, et al: Tumor-infiltrating DCs suppress nucleic acid-mediated
innate immune responses through interactions between the receptor
TIM-3 and the alarmin HMGB1. Nat Immunol. 13:832–842. 2012.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao
D, Liu Y, Zhu F, Zhang L, Sun W, et al: T cell immunoglobulin- and
mucin-domain-containing molecule-3 (Tim-3) mediates natural killer
cell suppression in chronic hepatitis B. J Hepatol. 52:322–329.
2010. View Article : Google Scholar : PubMed/NCBI
|
32
|
Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y
and Chen Z: Blockade of Tim-3 signaling restores the virus-specific
CD8+ T-cell response in patients with chronic hepatitis
B. Eur J Immunol. 42:1180–1191. 2012. View Article : Google Scholar : PubMed/NCBI
|